AXIM Biotechnologies and Medical Marijuana, Inc. Form Strategic Alliance to Develop Water-Soluble Cannabinoid Technology

AXIM Biotechnologies, Inc. and Medical Marijuana, Inc. have announced a strategic alliance to research and develop applications for AXIM's patent covering water-soluble cannabinoids. The collaboration centers on AXIM's U.S. Patent No. 11,542,226 B2, which addresses a fundamental limitation of traditional cannabinoids: their inability to dissolve in water, significantly impairing absorption by the body. AXIM has assigned Medical Marijuana, Inc. a fifty percent right, title, and economic interest in the patent and all associated intellectual property, including rights to existing and future patents, licensing proceeds, and claims for past infringement.

Concurrently, the companies entered into a consulting agreement where AXIM will provide research and development services focused on developing applications for the patent technology. Catalina Valencia, AXIM President, stated that the alliance presents both companies with the ability to accelerate uses of the patent technology, noting that water solubility of CBD and other cannabinoids represents a significant development for improved administration and increased potency. Valencia suggested the patent could result in developing a drug or treatment, likely in sublingual form, able to treat conditions including anxiety or seizures.

Dr. Scott, MJNA Chairman and President, expressed confidence in AXIM's ability to provide R&D support for developing commercialized uses of the patent technology, calling the potential for enhanced administration of water-soluble cannabinoids a major development for MJNA. The patent's technological advantages include patented molecular engineering that links cannabinoids to complementary compounds, improving delivery mechanisms and therapeutic effectiveness. The engineered polyfunctional cannabinoids are more than 300 times more water-soluble than natural cannabinoids, enabling significantly improved absorption and therapeutic delivery.

These polyfunctional constructs are engineered to produce more potent responses and efficacy than individual cannabinoid molecules, potentially allowing for lower therapeutic doses while avoiding toxic side effects associated with higher concentrations. The technology offers treatment potential for conditions where traditional lipophilic cannabinoids have demonstrated limited bioavailability, including development of sublingual applications for anxiety and other indications. Medical Marijuana, Inc. paid $600,000 to AXIM as consideration for the assignment of the 50% interest in the patent through a secured promissory note, while the consulting agreement includes a monthly services fee of $62,500 paid to AXIM with an initial term expiring in January 2027.

The alliance combines AXIM's patented water-soluble cannabinoid technology with Medical Marijuana, Inc.'s market knowledge and relationships in the cannabinoid arena. This strategic partnership represents a significant development in cannabinoid research, potentially overcoming key limitations in cannabinoid administration that have hindered therapeutic applications. The enhanced bioavailability and reduced toxicity of water-soluble cannabinoids could expand treatment options for various medical conditions, making cannabinoid therapies more effective and accessible to patients who could benefit from their therapeutic properties.